Health Canada authorizes health claims for Pylopass™

The Canadian health authority has authorized the use of six claims, including the functional claim that Pylopass is “clinically shown to support the reduction of H. pylori when used in conjunction with physician-supervised antibiotic therapy”. Other claims include “helps to reduce abdominal pain related to Helicobacter pylori infection” and “an adjunct to physician-supervised antibiotic therapy in patients with Helicobacter pylori infections”. 

Pylopass is the only product in the database that carries the health claim “clinically shown to support the reduction of H. pylori when used in conjunction with physician-supervised antibiotic therapy”. This is a true testament to our One-in-a-trillion approach and our ambition to develop clinically backed solutions to human health challenges. 

Find the claims related to Pylopass here (please use Microsoft Edge to access). 

You can read more about NHPs here.